Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

CANNANNEW REPORT

– Demand for Therapeutic DNA Drives Inquiries for Bulk LinearDNA – STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #CARTcell—Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its majority-owned subsidiary LineaRx, Inc., a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization (CRO) order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research. PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. LineaRx has recorded an uptick in CRO orders for LinearDNA in recent quarters. Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year1. As a result of the COVID-19 pandemic, nucleic acid therapies have also moved to the forefront of biotherapeutic science with the successful deployment of mRNA vaccines against the virus. Most evaluations of LinearDNA currently center on its use in the development of preclinical CAR T therapies, a use case highlighted in a recently published study that utilized LinearDNA in a non-viral manufacture of CD19-specific CAR T cells2. CRO customers are also evaluating LinearDNA for use in mRNA template manufacture, recombinant adeno-associated virus manufacture, and in vivo expression vectors. Applied DNA and LineaRx CEO Dr. James A. Hayward stated, “We view CRO orders…

Excerpt only …
READ MORE BELOW
Source : Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.